List of Excipients in Branded Drug RUGBY OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION

Generic Drugs Containing RUGBY OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION

Company	Ingredient	NDC	Excipient
RUGBY LABORATORIES	olopatadine hydrochloride ophthalmic solution	0536-1445	BENZALKONIUM CHLORIDE
RUGBY LABORATORIES	olopatadine hydrochloride ophthalmic solution	0536-1445	HYDROCHLORIC ACID
RUGBY LABORATORIES	olopatadine hydrochloride ophthalmic solution	0536-1445	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in RUGBY OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION?

# Of NDCs	Excipient
1	BENZALKONIUM CHLORIDE
1	HYDROCHLORIC ACID
1	SODIUM CHLORIDE

Rugby Olopatadine Hydrochloride Ophthalmic Solution: Excipient Strategy and Commercial Opportunities

Last updated: August 19, 2026

Rugby Olopatadine Hydrochloride Ophthalmic Solution is a mature generic ophthalmic antihistamine and mast-cell stabilizer positioned against Patanol, the olopatadine hydrochloride 0.1% reference product. Its commercial value is driven less by active-ingredient exclusivity and more by manufacturing reliability, preservative selection, bottle performance, private-label distribution, and migration into differentiated formulations.

The likely 0.1% formulation uses a conventional aqueous vehicle containing benzalkonium chloride, phosphate buffer, sodium chloride, pH adjusters, and purified water. The principal commercial opportunity is to improve tolerability and convenience through preservative-free or lower-preservative presentations, multidose delivery systems, and higher-strength products such as olopatadine 0.2% and 0.7%.

What is Rugby Olopatadine Hydrochloride Ophthalmic Solution?

Rugby Olopatadine Hydrochloride Ophthalmic Solution is a generic topical ophthalmic product for allergic conjunctivitis. Olopatadine combines antihistaminic activity with mast-cell stabilization and is administered directly to the ocular surface.

Product attribute	Likely Rugby 0.1% product profile
Active ingredient	Olopatadine hydrochloride
Strength	0.1%, equivalent to approximately 0.111% olopatadine hydrochloride depending on label expression
Dosage form	Sterile ophthalmic solution
Route	Topical ocular
Therapeutic class	Ophthalmic antihistamine and mast-cell stabilizer
Reference product	Patanol 0.1% ophthalmic solution
Primary indication	Allergic conjunctivitis
Typical dosing	One drop in each affected eye twice daily
Market status	Generic prescription ophthalmic product
Main commercial risks	Price erosion, preservative intolerance, commodity manufacturing, limited product differentiation

The exact Rugby NDC and strength control the applicable label, package configuration, inactive-ingredient statement, and regulatory assessment. Rugby-branded ophthalmic products are commonly distributed through private-label and generic channels rather than marketed as innovation-led brands.

What excipients are used in Rugby Olopatadine ophthalmic solution?

The conventional olopatadine hydrochloride 0.1% ophthalmic solution formulation uses the following excipient architecture:

Excipient or component	Function	Commercial and technical relevance
Benzalkonium chloride, generally 0.01%	Preservative	Controls microbial growth in multidose packaging; can cause ocular-surface irritation with repeated use
Dibasic sodium phosphate	Buffer component	Helps maintain pH and olopatadine chemical stability
Sodium chloride	Tonicity adjustment	Helps bring the solution toward ophthalmic osmolality
Hydrochloric acid and sodium hydroxide	pH adjustment	Controls final formulation pH and may support solubility and comfort
Purified water	Vehicle	Continuous aqueous phase and principal formulation component

The formulation is intentionally simple. Olopatadine hydrochloride is water-soluble, so the product does not require an oil phase, surfactant system, suspending agent, or complex solubilizer. The principal formulation controls are pH, osmolality, preservative effectiveness, clarity, sterility, and container-closure compatibility.

FDA labeling for olopatadine ophthalmic solution identifies the inactive ingredients and describes the product as a sterile topical ophthalmic solution. The FDA Inactive Ingredient Database provides a regulatory reference point for excipient precedent in ophthalmic products. [1,2]

Why benzalkonium chloride matters commercially

Benzalkonium chloride, or BAK, is an effective and widely used ophthalmic preservative. It supports multidose packaging and simplifies manufacturing and distribution. Its disadvantage is cumulative ocular-surface exposure. Frequent use can contribute to epithelial irritation, tear-film instability, and discomfort, especially in patients with chronic allergic disease, dry eye, contact-lens use, or concomitant glaucoma therapy.

BAK therefore creates a commercial tradeoff:

• Lower manufacturing and packaging cost.
• Familiar regulatory precedent.
• Broad multidose usability.
• Potential tolerability disadvantage.
• Limited differentiation from competing generic products.

For Rugby’s conventional product, BAK is an efficiency-oriented excipient choice. For a differentiated successor product, BAK is the primary formulation feature to reconsider.

How does the Rugby formulation compare with competing olopatadine products?

Olopatadine products differ mainly by concentration, dosing frequency, preservative design, and marketing channel.

Product category	Representative strength	Typical dosing profile	Preservative position	Commercial role
Generic olopatadine ophthalmic solution	0.1%	Twice daily	Often BAK-preserved	Low-cost prescription substitution
Patanol	0.1%	Twice daily	Conventional preserved formulation	Original prescription reference
Pataday, prescription-era product	0.2%	Once daily	Product-specific formulation	Convenience-driven branded alternative
OTC Pataday products	0.2% or 0.7%, depending on product	Once daily	Product-specific	Consumer seasonal-allergy market
Preservative-free olopatadine concepts	0.1% to 0.7% potential range	Product-dependent	No BAK or alternative preservative	Premium tolerability segment

The largest competitive gap for a Rugby 0.1% product is once-daily convenience. A 0.1% twice-daily generic competes primarily on price. A 0.2% or 0.7% product can compete on dosing convenience, but it enters a more crowded branded and OTC environment.

What excipient strategies could improve Rugby olopatadine commercial value?

Preservative-free multidose delivery

A preservative-free multidose bottle is the strongest formulation opportunity. It would require a closure system that prevents microbial ingress without BAK. Suitable technologies can include one-way valves, filtered air systems, antimicrobial container components, or mechanically protected dispensing systems.

The technical burden is higher than for a conventional BAK-preserved bottle. Development must address:

• Sterility throughout in-use life.
• Drop-size consistency.
• Priming and repriming behavior.
• Container-closure integrity.
• Tip contamination.
• Extractables and leachables.
• Compatibility with olopatadine and buffer salts.
• Usability for elderly patients.

A preservative-free system can support premium pricing and improve positioning for patients with ocular-surface sensitivity. The container, rather than the excipient alone, is likely to carry much of the defensible IP.

Unit-dose preservative-free packaging

Unit-dose vials provide a simpler path to preservative avoidance. They eliminate the need for multidose antimicrobial protection but increase packaging material, filling operations, transport volume, and waste.

Attribute	Preserved multidose	Preservative-free unit dose
Packaging cost	Lower	Higher
In-use contamination control	Preservative-dependent	Single-use dependent
Patient convenience	High for routine use	Lower after opening
Ocular-surface positioning	Standard	Stronger
Distribution complexity	Lower	Higher
IP opportunity	Moderate	Moderate, mainly packaging and manufacturing

Unit-dose packaging is commercially attractive for specialty ophthalmology, hospitals, pediatric use, and patients with concomitant preserved eye-drop exposure. It is less attractive for high-volume discount retail unless manufacturing scale is substantial.

Alternative preservatives

Alternative preservatives such as polyquaternium-1 or stabilized oxychloro complex may reduce some tolerability concerns compared with BAK, but they do not create a preservative-free product. They also introduce new compatibility, toxicity, stability, and regulatory questions.

An alternative-preservative strategy is most useful when:

• The product must remain multidose.
• The target market accepts a modest premium.
• A completely preservative-free delivery system is not economically feasible.
• The developer has a defensible safety or tolerability dataset.

The commercial advantage is narrower than for preservative-free delivery because the product remains exposed to the broader criticism directed at preserved ophthalmic products.

Buffer and tonicity optimization

A formulation using a lower buffer load, an optimized phosphate system, or an alternative buffer could improve comfort and reduce precipitation risk. This approach is technically lower risk but has limited marketing value unless supported by comparative tolerability data.

The development program should measure:

• pH drift during storage.
• Osmolality.
• Assay and degradation products.
• Visible and subvisible particulate matter.
• Preservative concentration over shelf life.
• Drop volume and delivered dose.
• Ocular comfort in comparative studies.

A formulation with the same active strength and indication may be eligible for an abbreviated regulatory pathway, but meaningful formulation changes can require new bioequivalence, stability, safety, or clinical support.

What patents protect olopatadine ophthalmic formulations?

The core olopatadine composition and original ophthalmic use patents are mature and generally do not provide a meaningful exclusivity barrier to a Rugby generic product. The commercial patent opportunity now lies in formulation and delivery improvements.

Potentially relevant patent families include:

• Olopatadine composition-of-matter patents.
• Ophthalmic solution patents covering concentration, pH, dosing, or stability.
• Once-daily formulation patents.
• Preservative-free delivery-system patents.
• Multidose container-closure patents.
• Unit-dose packaging and manufacturing patents.
• Combination products containing olopatadine and another ophthalmic active.

The key distinction is between protecting olopatadine itself and protecting a particular product architecture. A new patent cannot ordinarily recreate broad active-ingredient exclusivity after the original compound patents have expired. A viable filing would need a novel and nonobvious formulation, delivery system, manufacturing process, or clinically relevant performance result.

What patent claims are commercially valuable?

The strongest formulation claims would connect a defined excipient system to a measurable technical result, such as:

• Improved chemical stability at a specified pH range.
• Reduced degradation during accelerated storage.
• Preservative-free sterility maintenance during in-use testing.
• Controlled drop size and dose uniformity.
• Reduced ocular irritation.
• Improved retention or residence time.
• Compatibility with a specific low-surface-energy bottle or valve.
• Reduced adsorption to container components.

Claims that merely recite common ophthalmic excipients at routine concentrations are vulnerable to obviousness challenges. The strongest protection generally combines composition limits with performance data and a specific container-closure system.

When does olopatadine lose exclusivity?

The original olopatadine exclusivity period has already ended. Generic competition is established, and Rugby’s commercial position depends on the approved generic product rather than a remaining compound patent monopoly.

Exclusivity category	Status for mature olopatadine 0.1% generic
New chemical entity exclusivity	Expired
Original composition patents	Generally expired or commercially exhausted
Reference-product regulatory exclusivity	Expired
Generic approval pathway	Established
Paragraph IV leverage	Primarily relevant only to later-listed patents or new product versions
Current protection	Manufacturing know-how, supply reliability, trademarks, packaging, and any product-specific patents

Orange Book analysis remains necessary for the specific reference product and any listed patents associated with later olopatadine strengths or formulations. [3] The absence of broad active-ingredient exclusivity does not eliminate risk from formulation or delivery patents.

What is the Orange Book and FDA regulatory status of Rugby olopatadine?

Rugby’s product is regulated as an approved generic ophthalmic drug if marketed under an ANDA. The Orange Book is used to identify reference-listed drugs, approved generic equivalents, therapeutic-equivalence codes, and patents or exclusivity associated with listed products. [3]

For a generic olopatadine ophthalmic solution, the core regulatory requirements typically include:

• Pharmaceutical equivalence to the reference product.
• Demonstrated sameness of active ingredient and strength.
• Sterility assurance.
• Appropriate ophthalmic manufacturing controls.
• Stability data.
• Container-closure qualification.
• Preservative effectiveness where applicable.
• Labeling consistent with the approved reference product.
• Bioequivalence or other product-specific equivalence evidence.

The principal regulatory distinction is between an ANDA generic matching the reference product and a new drug application for a materially differentiated product. A preservative-free multidose system, new strength, or materially different dosing regimen may require a regulatory strategy beyond a simple generic application.

Are Paragraph IV challenges relevant to Rugby olopatadine?

Paragraph IV challenges are most relevant when a generic applicant seeks approval before expiration of a listed patent. For the mature 0.1% olopatadine market, the main patent barriers have generally passed, so Paragraph IV activity is unlikely to be the central commercial issue for the established Rugby product.

Paragraph IV risk can reappear in three situations:

1. A later-generation olopatadine formulation has newly listed patents.
2. A preservative-free or controlled-delivery product receives new product-specific patents.
3. A higher-strength or new dosing formulation has Orange Book-listed patents.

A future generic entrant could challenge formulation patents covering 0.2%, 0.7%, once-daily dosing, or specialized container systems. Patent risk should be assessed against the exact NDA, strength, dosage regimen, and listed patent set rather than against olopatadine as a molecule.

Which companies are challenging Rugby’s commercial position?

Rugby competes with large generic manufacturers, private-label suppliers, branded ophthalmic companies, and OTC allergy brands. The relevant competitive groups include:

• Generic manufacturers offering olopatadine 0.1%.
• Branded products based on olopatadine 0.2% or 0.7%.
• Ketotifen ophthalmic products.
• Prescription antihistamine and mast-cell stabilizer products.
• Preservative-free allergy drops.
• Retail pharmacy private-label products.
• Online and mass-market OTC allergy brands.

Competition is segmented. Low-price generics compete for prescription substitution and payer control. Branded and OTC products compete on once-daily dosing, consumer recognition, packaging, and seasonal merchandising. Preservative-free products compete on tolerability and specialty-care use.

What commercial opportunities exist for Rugby olopatadine?

Private-label and payer contracts

The existing 0.1% product is well suited to private-label and institutional distribution. The commercial differentiators are:

• Reliable API supply.
• Low cost per bottle.
• High fill-finish throughput.
• Stable preservative performance.
• Consistent drop size.
• Low back-order risk.
• Multiple bottle and carton configurations.

For a mature generic, supply continuity can be more valuable than marginal formulation novelty.

OTC expansion

Olopatadine has a significant OTC commercial pathway in the United States through approved nonprescription products. OTC commercialization requires consumer-directed labeling, packaging, safety communication, and retail execution. A Rugby-branded OTC product would compete against established shelf brands and would require more than an ANDA-based generic strategy.

An OTC opportunity is strongest for:

• Seasonal allergy campaigns.
• Once-daily dosing.
• Recognizable consumer packaging.
• Retail and e-commerce distribution.
• Preservative-free positioning.
• Family and contact-lens-user segments, subject to labeling limitations.

Higher-strength formulations

A 0.2% once-daily formulation offers a direct convenience advantage over a 0.1% twice-daily product. A 0.7% formulation can support a premium OTC or branded-generic strategy, but competition and regulatory requirements are higher.

The commercial return depends on whether the developer can secure:

• A differentiated label.
• A defensible formulation or delivery patent.
• A reliable product profile.
• Retail access.
• Acceptable manufacturing cost.
• A clear tolerability or convenience claim.

Preservative-free specialty product

A preservative-free product could target chronic allergy sufferers, patients with dry eye, contact-lens users, and patients receiving multiple ophthalmic medications. The market is smaller than the standard generic segment but can support higher net pricing.

The most attractive product concept is a preservative-free, once-daily, multidose bottle with validated in-use sterility and a controlled, low-volume drop. Its commercial value would depend heavily on packaging performance and patient usability.

What manufacturing and intellectual-property barriers exist?

The active ingredient is not the primary barrier. The main barriers are:

• Sterile ophthalmic filling capacity.
• Container-closure integrity.
• Preservative effectiveness.
• Low-bioburden process control.
• Extractables and leachables.
• Drop-volume consistency.
• In-use stability.
• Device assembly and supply.
• Validated cleaning and sterilization processes.
• Patent clearance for the dispensing system.

A conventional BAK-preserved product has relatively low technical complexity. A preservative-free multidose product has higher capital and validation requirements but also offers stronger differentiation and potentially higher margins.

Manufacturing know-how can create practical protection even when patent protection is limited. Process parameters affecting clarity, sterility, filling accuracy, and bottle performance may be difficult for a low-cost entrant to reproduce quickly. That protection is operational rather than statutory and can erode when contract manufacturers or device suppliers are shared across competitors.

How strong is the Rugby olopatadine patent estate?

The patent estate for the established Rugby 0.1% generic product is likely weak as a standalone commercial moat because:

• Olopatadine is a mature active ingredient.
• Generic equivalents are available.
• Original compound and basic ophthalmic-use protection are no longer central barriers.
• The product uses conventional excipients.
• The brand is primarily a distribution and supply vehicle.

Patent strength would improve only through a new formulation or delivery system supported by comparative performance data. The most defensible asset would combine a novel preservative-free multidose package with defined formulation parameters and validated in-use sterility.

What generic launch scenarios exist?

Launch scenario	Timing profile	Price effect	Strategic assessment
Additional 0.1% generic entrant	Immediate in mature market	High erosion risk	Commodity competition
Private-label expansion	Short to medium term	Moderate to high erosion	Distribution-led growth
Generic 0.2% once-daily product	Regulatory-dependent	Moderate erosion with premium potential	Stronger convenience proposition
Generic 0.7% product	Regulatory and commercial dependent	Potential premium	Higher competitive intensity
Preservative-free unit dose	Development-dependent	Premium but higher cost	Specialty and tolerability niche
Preservative-free multidose	Development and device-dependent	Highest differentiation potential	Strongest IP and margin opportunity

What revenue exposure does olopatadine create?

Revenue exposure is concentrated in unit volume rather than patent-protected pricing. A conventional 0.1% product is vulnerable to:

• Payer-mandated generic substitution.
• Multiple approved ANDA suppliers.
• Retail pharmacy purchasing pressure.
• Seasonal demand variability.
• API and bottle shortages.
• Contract manufacturing concentration.
• OTC brand competition.

A differentiated product can reduce price exposure by shifting the value proposition toward convenience or tolerability. The revenue pool is more attractive when the product is sold through a private-label, specialty, or OTC channel rather than as an undifferentiated reimbursed generic.

Key Takeaways

• Rugby Olopatadine Hydrochloride Ophthalmic Solution is a mature generic ophthalmic antihistamine product, most commonly associated with the 0.1% strength.
• Its conventional excipient system relies on benzalkonium chloride, phosphate buffering, sodium chloride, pH adjustment, and purified water.
• BAK supports low-cost multidose packaging but limits differentiation because of ocular-surface tolerability concerns.
• The core olopatadine patent barrier has largely expired; current value is tied to supply, manufacturing, packaging, and distribution.
• The strongest commercial opportunity is a preservative-free multidose product with a defensible dispensing system.
• A 0.2% once-daily or 0.7% product can create more commercial value than another 0.1% generic, but regulatory and competitive barriers are higher.
• Paragraph IV risk is limited for the mature 0.1% market and more relevant to later-strength, once-daily, or device-protected formulations.
• The most durable IP would protect a specific formulation-device combination supported by stability, sterility, drop-performance, and tolerability data.

FAQs

Is Rugby olopatadine ophthalmic solution preservative-free?

The conventional Rugby olopatadine hydrochloride ophthalmic solution is generally BAK-preserved. A product-specific label should be used to confirm the exact inactive-ingredient statement for the relevant NDC.

Can Rugby olopatadine be used with contact lenses?

Patients generally remove contact lenses before administration when the product contains benzalkonium chloride. The product label controls the permitted interval before reinsertion and any specific contact-lens instructions.

Is olopatadine 0.1% therapeutically equivalent to Patanol?

An FDA-approved generic olopatadine 0.1% ophthalmic solution may be therapeutically equivalent to Patanol when assigned the applicable Orange Book equivalence code. Equivalence depends on the approved product and listing, not on the active ingredient alone.

Does olopatadine ophthalmic solution have biosimilar risk?

No. Olopatadine is a small-molecule drug, not a biologic. Competitive risk comes from generic ANDA products, branded generics, OTC products, and reformulated ophthalmic presentations rather than biosimilars.

Can a new excipient create patent protection for olopatadine eye drops?

An excipient alone rarely creates strong protection. A patent is more commercially defensible when it claims a novel excipient combination or delivery system linked to improved stability, sterility, tolerability, residence time, or dose uniformity.

References

1. U.S. Food and Drug Administration. (n.d.). DailyMed: Olopatadine hydrochloride ophthalmic solution labeling. National Library of Medicine.

2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

5. U.S. Food and Drug Administration. (n.d.). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin. FDA.